Why Edgewise Therapeutics Stock Crushed the Market on Monday

One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech. She has flagged it as one of her firm's best stock ideas for this year.

The Motley Fool • Feb 10, 2026

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D.

PRNewsWire • Feb 5, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on January 30, 2025, Edgewise granted inducement stock options to purchase a total of 198,250 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

PRNewsWire • Feb 2, 2026

Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT (11:15 am ET) - BOULDER, Colo.

PRNewsWire • Jan 13, 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D.

PRNewsWire • Jan 6, 2026

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits

California-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter. The overall position value fell by about $7.67 million from the previous period.

The Motley Fool • Dec 29, 2025

Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. Key 2026 catalysts include phase 2 CIRRUS-HCM efficacy data in Q2 2026 and potential phase 3 initiation for EDG-7500 in Q4 2026, targeting both oHCM and nHCM patients.

Seeking Alpha • Dec 29, 2025

Why Did Edgewise Therapeutics Jump 25%+ On Wednesday?

Edgewise Therapeutics (EWTX) surged nearly 26% following the release of favorable interim safety and efficacy data from its Phase 2 CIRRUS-HCM trial for EDG-7500, an oral cardiac sarcomere modulator for hypertrophic cardiomyopathy. This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust institutional buying.

Forbes • Dec 26, 2025

Why Edgewise Therapeutics Stock Rocked the Market Today

The biotech gifted quite a holiday present to its investors. An investigational drug continues to show significant promise.

The Motley Fool • Dec 24, 2025